STAT

Congress isn’t acting to curb drug prices, so states are stepping up. Here’s how

With little action in Congress, states from California to Vermont are experimenting with ways to try to curb drug prices or shine a light on rising costs.

President Trump has complained that drug makers are getting away with murder — and he may be right.

Despite vociferous complaints from consumers that drug prices are too high, Congress has failed to act. And with few exceptions, the pharmaceutical industry has successfully delayed or thwarted state bills that would force drug makers to explain or justify price hikes.

But that may be starting to change. Last week, of the pharma industry, already has a similar policy in place.  recently began requiring drug makers to disclose pricing data about diabetes medicines. And has a new law that penalizes generic companies for price gouging.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Health Care Leaders Plot How To Expand Diversity In Clinical Trials
Experts gathered at the Milken Institute Global Conference this week to discussed potential strategies to expand diversity in clinical trials. Here are some of their big ideas.
STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks